All In Biotech

Drug Trial Radar · NCT04817189

Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)

MyRisk: Efficacy and Safety Evaluation of Oral Akynzeo® in Patients Receiving MEC at High Risk of Developing CINV Based on a Prediction Tool: A Multinational and Multicenter Study

Last checked: Nov 20, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 414 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

414

Actual

Start

Feb 1, 2021

Primary completion

Jul 2, 2024

Study completion Jul 2, 2024

Sponsor

Lead sponsor
Helsinn Healthcare SAIndustry
Sponsor type
Industry
First posted
Mar 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Supportive care
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

MyRisk: Efficacy and safety evaluation of oral Akynzeo® in patients receiving MEC at high risk of developing CINV based on a prediction tool. A multinational and multicenter study. Antiemetic guidelines recommendations are based on the emetogenic potential of the chemotherapy. Chemotherapy (CT) agents are divided in Highly, Moderately, Low and Minimally Emetogenic potential. In addition to type of chemotherapy, several patient-related risk factors can increase the risk of CINV (chemotherapy-induced nausea and vomiting). Currently, there is limited consensus surrounding the most relevant patient risk factors that may predict the risk of CINV. Based on a recent study by Dranitsaris et al. (Dranitsaris et al. Ann Oncol. 2017 Jun 1; 28(6):1260-1267.), eight (8) predictive factors have been identified and an algorithm has been developed to incorporate these factors into the optimal selection of prophylactic antiemetics: 1. nausea and/or vomiting in the prior cycle of chemotherapy 2. use of non-prescribed antiemetics at home in the prior cycle of chemotherapy 3. platinum or anthracycline-based chemotherapy 4. age \< 60 years 5. expectations for (anticipating) nausea and/or vomiting 6. \<7 h of sleep the night before chemotherapy 7. history of morning sickness during previous pregnancy 8. cycle of chemotherapy (A negative association between risk and number of cycles was identified where the hazard for CINV was highest in cycles 1 and 2, with a gradual decline and plateau from cycle 3 onward). The clinical application of this prediction tool has the potential to be an important resource for clinicians and may help to enhance patient care by optimizing the use of the antiemetics in a proactive manner.

Conditions

  • Chemotherapy-induced Nausea and Vomiting

Interventions

  • NEPA (300mg netupitant/0.5mg palonosetron)Drug

    Oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle.

  • Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV)Drug

    Standard of care will be administered on Day 1 of each cycle.

  • Dexamethasone, 8 mg (oral) or equivalent IV doseDrug

    Dexamethasone (8 mg) will be administered on Day 1 of each cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Probability of Complete Responses Over Three Cycles of Chemotherapy After the Start of the MEC AdministrationTime frame: At the end of all three chemotherapy cycles. The length of a cycle depends on the treatment being given (cycles range from 2 to 6 weeks).

Locations

19 sites in 7 countries. Site status is shown where the registry gives one.

  • Shanghai Chest Hospital

    Shanghai, China

  • Shanghai Ninth People´s Hospital

    Shanghai, China

  • Shanghai Obstetrics and Gynecology Hospital

    Shanghai, China

  • Thomayerova nemocnice

    Prague, Czechia

  • General University Hospital in Prague

    Prague, Czechia

  • Evang. Kliniken Essen-Mitte

    Essen, Germany

  • Universitätsmedizin Mannheim

    Mannheim, Germany

  • München Klinik Neuperlach

    München, Germany

  • Frauenklinik St. Louise

    Paderborn, Germany

  • Klinikum Ernst von Bergmann gemeinnützige GmbH

    Potsdam, Germany

  • Sotiria General Hospital, 3rd Deúpartment of Medicine, School of Medicine, National and Kapodistrian University of Athens

    Athens, Greece

  • General University Hospital of Heraklion

    Heraklion, Greece

  • Complejo Hospitalario Universitario de A Coruña

    A Coruña, Spain

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

  • Hospital General Universitario Gregorio Marañón

    Madrid, Spain

  • Hospital Universitario de Salamanca

    Salamanca, Spain

  • University Hospital Basel

    Basel, Switzerland

  • Swiss Medical Network - Clinique de Genolier

    Genolier, Switzerland

  • The Royal Marsden Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.